ICML 2023 | Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trial
Barbara Eichhorst
• 14 Jun 2023
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, shares the findings of the seven-year follow-up analysis of the Phase III MURANO study (NCT02005471) investigating venetoclax and rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Dr Eichhorst highlights the outcomes from a sub-study in which patients were retreated with VenR, which suggest that retreatment is a viable option for patients with R/R CLL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
